Diabetes drug could help treat bipolar depression
NCT ID NCT07472920
Summary
This study is testing whether empagliflozin, a medication approved for type 2 diabetes, might help reduce depression symptoms in people with bipolar disorder who also have insulin resistance. Twenty adults with bipolar depression will take empagliflozin alongside their current medications for 12 weeks. Researchers want to see if improving the body's insulin response can help both mood symptoms and metabolic health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Psychiatry, University of São Paulo Medical School (IPq-FMUSP)
São Paulo, São Paulo, 05403-903, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.